Method of treatment intervertebral disk disease in dogs

FIELD: veterinary medicine.

SUBSTANCE: method of treatment of intervertebral disk disease in dogs comprises administering the medicinal product, and the medicinal product is used as 10-30% aqueous solution of polyethylene glycol-4000, which is administered subcutaneously in an amount of 2-4 ml/kg of animal body weight every second day for 5-7 days.

EFFECT: improvement of efficiency of the method.

1 ex

 

The invention relates to veterinary medicine and can be used in the treatment of compressive lesions of the spinal cord, in particular for the treatment of dogs with intervertebral disk.

There is a method of treatment of intervertebral disc hernia in dogs, including intravenous drugs, in particular intravenous methylprednisolone 2 times a day for 5 days (Hall E and Joe E. Springer Neuroprotection and Acute Spinal Cord Injury." A Reappraisal NeuroRx. 2004 January; 1(1): pp.80-100).

The disadvantage of this method is the lack of degree of cure.

Objective of the claimed technical solution is to increase the effectiveness of treatment by increasing the degree of support ability of animals.

The problem is solved in a method of treatment of dogs with intervertebral disk, including subcutaneous administration of a medicinal product, as a medicinal product use 10-30% aqueous solution of polyethylene glycol-4000 based 2-4 ml/kg of body weight of the animal every other day for 5-7 days.

Known polyethylene glycol-4000 (PEG) polyethylene glycol of high molecular weight /THE 2483-008-71150986-2006 with ISM. 1, 2/ - a synthetic polymer that is used when conducting genetic recombination in bacterial cells to induce the fusion of protoplasts (Source: Microbiology: a Glossary", N. Firsov.N., M: Draw the and, 2006).

The proposal was feasible in the laboratory, aimed at solving real technical problem, i.e. the sentence "industrially applicable".

The authors first established that the use as a drug subcutaneous injection 10-30% aqueous solution of polyethylene glycol-4000 based 2-4 ml/kg of body weight of the animal every other day for 5-7 days in the treatment of herniated intervertebral discs in dogs can increase the weight-bearing capacity of animals due, apparently, competition PEG with water damage membranes of axons, i.e., the proposal meets the criteria of "novelty" and "inventive step".

The method is illustrated by the following examples.

Example 1. Picked up 3 groups of 10 dogs breed Dachshund on the principle of analogues with a 4-th degree of the violations by Danny X (2004) - (Orthopedics dogs and cats 594 S., X. Denny, C. Butterwoth, Moscow, Aquarium ISBN 978-5-98435-672-5, 0-632-05103-5; 2007).

group 1 dogs were treated with subcutaneous injection of 10% aqueous solution of polyethylene glycol-4000 at the rate of 2 ml/kg body weight of the animal every other day for 5 days.

group 2 dogs were treated with methylprednisolone in the initial dose 30 mg/kg, followed by 12 hours 15 mg/kg, then 5 mg/kg of body weight of the animal is intravenously 2 times a day for 5 days.

group 3 dogs were untreated (subcutaneously injected f is trustwor within 5 days).

Results for 2 months - 80% recovery support ability in the first group, 40% in the second group. In the group without treatment (group 3) recovered the weight-bearing capacity in 10% of dogs.

Example 2. Picked up 3 groups of 10 dogs breed Dachshund, selected on the principle of analogs with 5-th degree of the violations by Danny X (2004) - (Orthopedics dogs and cats 594 S., X. Denny, C. Butterwoth, Moscow, Aquarium ISBN 978-5-98435-672-5, 0-632-05103-5; 2007).

group 1 dogs were treated with subcutaneous injection of 30% aqueous solution of polyethylene glycol-4000 (4 ml/kg body weight of the animal every other day for 7 days.

group 2 dogs were treated with methylprednisolone in the initial dose 30 mg/kg, followed by 12 hours 15 mg/kg, then 5 mg/kg of body weight of the animal is intravenously 2 times a day for 7 days.

group 3 dogs were untreated (subcutaneously injected with a saline solution for 7 days).

Results for 2 months - 70% recovery support ability in the first group, 30% in the second group. In the group without treatment (group 3) recovered the weight-bearing capacity in 10% of dogs.

As shown by the experimental results, the proposed method for the treatment of hernias of intervertebral disks dogs can increase recovery support ability of the animals in 2-2,3 times in comparison with the known method of treatment. In addition to the, the proposed method reduces the number of injection the animal was more than two times in comparison with the known method, i.e., simplifies treatment method.

Method for the treatment of intervertebral disc hernia in dogs, comprising the administration of a medicinal product, characterized in that as a drug used subcutaneously 10-30% aqueous solution of polyethylene glycol-4000 based 2-4 ml/kg of body weight of the animal every other day for 5-7 days.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of general formula (I), possessing an activity with respect to cytokines, versions of based on them pharmaceutical compositions and their application. Formula (I) compounds can be applied for treatment or prevention asthma, COPD, ARDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis or gouty arthritis. In general formula (I) L is selected from the group, consisting of -C(O)-, -CH2-, Ar1 represents a mono-, di- or trisubstituted phenyl ring, where substituents are independently selected from the group, consisting of a halogen and -C1-4alkyl; Ar2 represents an optionally substituted thiadiazolyl ring, where the substituent represents -C1-4alkyl, -C3-5cycloalkyl, -methylcyclopropyl, phenyl or a 5- or 6-membered monocyclic heteroaromatic ring or a bicyclic heteroaromatic ring with 9 or 10 atoms, with the said heteroaromatic ring containing 1, 2 or 3 heteroatoms, selected from the group, consisting of S, O and N, where the said phenyl or heteroaromatic ring is optionally mono- or disubstituted with substituents, independently selected from the group, consisting of a halogen, -C1-6alkyl, optionally substituted with 1-4 fluorine atoms, -O-C1-6alkyl, -CF3 and oxo.

EFFECT: increased efficiency of the application of the compounds.

16 cl, 1 tbl, 46 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to traumatology and orthopaedics, and can be used for treating patients with epicondylitis. That is ensured by applying a complex of measures, in particular a restraint of motions in the involved segment, physiotherapy and drug treatment. A pain syndrome is pre-evaluated by a visual analogue scale (VAS). A proximal forearm is immobilised with an epicondylic bandage in the daytime for 7-10 days in sportsmen, and for 2-3 weeks in common patients. Therapeutic exercises (TE) are prescribed from the first day of treatment. The first part of TE consisting of isometric and static exercises aiming at strengthening arm muscles is done before noon. The second part of TE comprising relaxing exercises is performed in the late afternoon or after any physical loads. The patient continues with the therapeutic exercises after the bandage is removed and to be used for professional or sports loads only. Electric stimulation is conducted daily for 7-10 days with using TENS apparatus or its analogues generating electrical signals covering the enthesis and the involved forearm muscles. Arthrofoon is administered with underlying electric stimulation. If the pain syndrome value according to the VAS is less than 4 points, the preparation is administered as a monotherapy in a dose of 4 weeks a day for three months. If the pain syndrome according to the VAS is more than 4 points, Arthrofoon is administered in a dose of 8 tablets a day in a combination with a selective non-steroid anti-inflammatory preparation in a therapeutic dose for no more than 10 days. The therapeutic regimen also contains Sirdalud 2-4 mg one hour before bedtime for 2 weeks. There are also administered vasodilators improving microcirculation of the involved segment, intramuscularly for 10 days. The therapeutic complex is also added with Milgamma B 2 ml, 5 injections, and another 5 injections triduan. Wobenzyme is administered for 3-4 weeks. Calcemine or Calcemine-advance, the preparations of calcium are administered for six months. The therapeutic course according to the presented regimen is repeated half a year later. The physical exercising for the arm muscles strengthening are to be further done two or three times a week on the average for min. 30 minutes for the life term if suffering high loads or doing any top-class sports for the purpose of maintaining the forearm tonus. The segment of interest is fixed with an orthesis when suffering a load. The therapy with the TENS or similar apparatus of the forearm muscles of interest and the enthesis follow a pronounced load 2-3 hours before bedtime and shall be accompanied with a session of relaxing exercises.

EFFECT: method provides the evident and stable clinical effect characterised by the complete recurrence-free recovery by the physical restoration of the tissue structure within the inflammation with the high quality of life and a surgical intervention avoided.

1 dwg, 2 ex

FIELD: biotechnologies.

SUBSTANCE: invention proposes a molecule that is specifically combined with CD37 and that contains the following from N-end to C-end: (a) CD37-specific scFV containing the following from N-end to C-end: (i) humanized variable region of a heavy chain, which contains CDR1 GYNMN, CDR2 NIDPYYGGTTYNRKFKG and CDR3 SVGPFDS, (ii) linker having 5 to 30 aminoacids inclusive, and (iii) humanized variable region of an easy chain containing CDR1 RASENVYSYLA, CDR2 FAKTLAE and CDR3 QHHSDNPWT; (b) a link region; and (c) immunoglobulin regions CH2 and CH3. The following is described: The following is described: nucleic acid coding the above binding molecule; an expression vector containing the above nucleic acid; and a host cell for production of a binding molecule, which contains the above vector. The invention proposes use of the above binding molecule to obtain a medicinal agent to reduce the number of B-cells, treatment of a disease or an illness, which is related to abnormal activity of B-cells. Besides, the invention describes compositions containing effective number of the above binding molecule to reduce the number of B-cells, treatment of a disease or an illness related to abnormal activity of B-cells.

EFFECT: invention allows obtaining scFV molecule binding CD37, having orientation of variable regions VHVL, with high yield and efficiency in comparison to scFV molecule against CD37, which has orientation of variable regions VLVH.

31 cl, 17 dwg, 13 tbl, 12 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to biotechnology and represents a pharmaceutical composition applicable for treating a rheumatic disease and containing the humanised anti-CD4 antibody able to activate CD4+CD25+ regulatory T-cells, and methotrexat. The present invention also discloses a kit and a method of treating the rheumatic disease with using the above pharmaceutical combination and the above kit.

EFFECT: invention enables implementing more effective methods of treating the rheumatic diseases, including rheumatoid arthritis.

57 cl, 8 dwg, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine. What is described is a biological material containing: a) a liquid carrier containing a viscous solution containing at least one natural and/or semisynthetic polysaccharide and having a dynamic viscosity measured at 20°C and at shear rate D=350 s-1, within the range of 100 to 250 centipoise and/or kinematic viscosity within the range of 99 to 248 centistokes (measured in the same environment); b) a autologous or heterologous mesenchymal cell culture and/or c) platelet rich blood product.

EFFECT: material in form of viscous liquid is particularly applicable for the therapy of osteoarthritis, ligament injuries and administered intra-articularly, intradermally or applied in situ without change of the properties of the mesenchymal stem cells and/or its platelets.

11 cl, 5 ex

FIELD: medicine.

SUBSTANCE: method involves a preclinical electroneuromyography (ENMG) of the neuromuscular apparatus of injured and intact lower extremities to measure a muscle response amplitude - an M-response. The findings are recorded. Starting from the second postoperative day, in the course of the drug-induced neuroprotective treatment and therapeutic exercises, the following therapy is additionally performed for 10-15 days. If the injured M-response amplitude is below 4.0 mV, while the respective intact value is more than 4.0 mV, the anti-inflammatory physical treatment covering the injured extremity is performed. If the injured M-response amplitude is more than 4.0 mV, while the respective intact value is below 4.0 mV, the stimulating passive physical treatment covering the intact extremity is performed. If the M-response amplitude of the injured and intact extremities is below 4.0 mV, the anti-inflammatory physical treatment covering the injured extremity and the stimulating passive physical treatment covering the intact extremity are performed. Three and six months following the surgical management, the repeated ENMG of the neuromuscular apparatus of the lower extremities to measure the M-response amplitude. If observing the preserving M-response amplitude below 4.0 mV on at least one lower extremity three months following the surgical management, the repeated complex of the drug-induced neuroprotective treatment and the stimulating passive physical treatment covering the neuromuscular apparatus of the hip with the M-response amplitude below 4.0 mV are performed. If observing the preserving M-response amplitude below 4.0 mV on at least one lower extremity six months following the surgical management, the repeated complex of the drug-induced neuroprotective treatment and the stimulating passive physical functional treatment covering the neuromuscular apparatus of the hip with the M-response amplitude below 4.0 mV are performed by walking electrical stimulation of the hip and shin.

EFFECT: method reduces the length of treatment and increases its effectiveness with decreasing a percentage of neurological complications by performing the individual complex exposure on the neuromuscular apparatus of the lower extremities taking into account the ENMG findings of the neuromuscular apparatus of the lower extremities.

2 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula (I), wherein A means morpholinyl, 1,4-oxazepamyl, piperidinyl, pyrrolidinyl or azetidinyl which is bound to N; R1 means C1-C6-alkyl group; R2 means bicyclic aryl group specified in 1H-indolyl, 1H-pyrrolo[3,2-b]pyridyl, quinolyl, naphthyl, 1H-pyrrolo[2,3-b]pyridyl, 5H-pyrrolo[3,2-d]pyrimidinyl, 7H-pyrrolo[2,3-d]pyrimidinyl, benzo[b]thiophenyl, imidazo[1,2-a]pyridyl, benzo[b]thiazolyl, 5H-pyrrolol[2,3-b]pyrazinyl and quinoxalinyl which can be substituted by R4; R3 means hydrogen or halogen atom; R4 means C1-C6-alkyl group, C1-C6-halogenalkyl group, OR1A, halogen, -(CH2)aOH, CN, NHCOR1A, SO2R1A or NHSO2R1A; R5 means C1-C6-alkyl group, -(CH2)aOH, -(CH2)aOR1B, halogen or CONH2; provided p is a plural number, R5 can be identical or different, or R5 can be combined with another R5; each of R1A and R1B independently means C1-C6-alkyl group; a is equal to 0, 1 or 2; n is equal to 1 or 2; p is equal to 0, 1, 2, 3, 4 or 5. Besides, the invention refers to intermediate compounds of formulas (IA) and (IB) for preparing the compounds of formula (I), to a preventive or therapeutic agent containing the compounds of formula (I), pharmaceutical compositions, using the compounds of formula (I) and to a method for preventing or treating diseases.

EFFECT: compounds of formula (I) as selective 5-HT2B receptor antagonists.

11 cl, 1 dwg, 18 tbl, 88 ex

FIELD: medicine.

SUBSTANCE: what is described is a method for the cartilaginous, osseous, muscular tissue regeneration stimulation involving the setting of a long bone fracture and introduction of the prepared agent into the intramedullary canal and the surrounding muscular tissue; that is combined with the tissue regeneration stimulation by introducing a mixture of aqueous solutions of recombinant beta interferon (IFN-β) in the concentration of 1∙105 units/ml and polyethylene glycol with a molecular weight of 6,000 (PEG 6000) in the concentration of 0.03∙10-9 mole/ml in the relation of 1:4 respectively; that is followed by a retrograde intramedullary osteosynthesis of the long bone fracture.

EFFECT: agent enables providing higher clinical effectiveness in the long bone fractures, reducing injuries, simplifying preparation technology of the agent for the tissue regeneration stimulation within the fracture, and reducing a rate of pyoinflammatory complications.

10 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to novel inhibitors of human poly(ADP-riboso)polymerase-1 based on uracyl derivatives of general formula (I), (II), (III) and (IV). Inhibitors of poly(ADP-riboso)polymerase-enzymes take part in DNA reparation. In general formula and R1=H, Cl, Br, I, methyl, ethyl, propyl or isopropyl; R2, R3, R4, R5=H, methyl, ethyl, propyl or phenyl; R6=(CH2)n, where n=1-4; X=OR2 or NR2R3, R2, R3=H, methyl, ethyl, propyl, phenyl, 3-hydroxypropyl.

EFFECT: obtaining novel inhibitors of human poly(ADP-riboso)polymerase-1.

1 tbl, 19 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely traumatology, orthopaedics, and can be used for supporting treatment in large joint replacement. That is ensured by determining a volume of involved joint contracture six months before the operation. That is followed by X-ray and magnetic resonant examination of the involved and collateral joints to specify their state. Besides, a quality of the bone tissue is assessed by osteodensitometry. If observing changes in the bone tissue quality, the complex of the drug therapy is added with the preparations Bivalos and Calcemin. A pain syndrome intensity is assessed by the visual analogue scale three months before the operation. That is followed by the complex therapy aiming at optimising the state of extremity joints with added local injection therapy (LIT). That is ensured by preliminary exposing the biologically active periarticular zones in the proximal and distal direction from the involved joint to the focused infrared laser light. A mixture containing solutions of the therapeutic preparations: chondroprotectors, Contrykal, Lidocaine, vitamin B12 is injected into the same zones. Besides, Arthrofoon is administered for the whole preoperative period. If the pain syndrome intensity is less than 4 points, Arthrofoon is administered in a dose of 4 tablets a day. If the intensity value is more than 4 points, the preparation is administered in a dose of 8 tablets a day in a complex with a short course of a non-steroidal anti-inflammatory preparations and a chondroprotector. The replacement operation is immediately followed by fixing a collateral joint with an orthesis for the period of 3 months. The complex of the postoperative supporting therapy started three weeks after the operation is added with a single intravenous introduction of the preparation Aklasta, the preparation Arthrofoon in a dose of 4 tablets a day for three months, alpha calcidole and Calcemin continuously. A pectoral girdle of the extremities is reinforced by means of an individually specified set of therapeutic exercises and electric walking myostimulation. The LIT of the collateral joint is performed three months after the operation. If observing a degenerative process in the adjacent joints, the LIT is performed alternatively in these regions. Vasodilators, chondroprotectors, and the preparation Milgamma are administered with underlying LIT. If observing psychoemotional changes in the patient, the preparation Tenoten is additionally administered. A postoperative medication regimen, including the LIT is repeated 3-4 times every 6 months.

EFFECT: method provides optimising the effect of the surgical management and preventing developing complications both in the operated joint, and in the adjacent and symmetrical joints after the replacement, preventing developing instability of the endoprosthesis components, preventing developing or aggravating degenerative process in the symmetrical and adjacent joints that reduces a risk of the recurrent operations.

1 ex

FIELD: medicine.

SUBSTANCE: what is declared is an infusion solution for filling the deficiency and meeting the physiological needs for water and basic electrolytes, which contains the following ingredients: sodium (Na+) - 27.72-28.28 mmole/l; fumarate(H2C4O42-) - 13.86-14.14 mmole/l; potassium (K+) - 18.61-18.99 mmole/l; calcium (Ca2+) - 3.56-3.64 mmole/l; magnesium (Mg2+) - 2.18-2.22 mmole/l; chlorine (Cl-) - 30.0-30.6 mmole/l; glucose (C6H12O6) - 189.1-192.9 mmole/l, water for injections.

EFFECT: solution contains the basic electrolyte concentration balanced for meeting the physiological needs; it is safe for the clinical application and can be used in diseases of various aetiology for patients of any age.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: upon completion of the surgical intervention, before the abdominal wall closure, microirrigators are inserted through counteropenings into the hypochondria. An end of the right microirrigator is fixed with an interrupted catgut suture to a stump of the resected stomach; an end of the left microirrigator is fixed at an upper level of the abdominal cavity with the interrupted catgut suture. Drain tubes are inserted through the counteropenings in the iliac regions into the small pelvis. The surgical intervention is terminated with treating the whole abdominal cavity with 50 ml ozonised normal saline 1000 mcg/l. Then 10 minutes later, the abdominal cavity is treated with metronidazole 100 ml. From the 1st to 5th postoperative day, metronidazole 200 ml is administered in the form of 24-hour infusion through a portable infusion device via the right microirrigator. Through the left microirrigator, 50 ml ozonised normal saline 1000 mcg/l is administered once a day. A course of standard intravenous antibiotic therapy is prescribed into the patient.

EFFECT: reducing an incidence rate of postoperative infectious-inflammatory complications in the given category of patients due to the specific regimen of the antibacterial therapy and the ozone therapy.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery, and can be used in treating patients with pancreatonecrosis. For this purpose, opening the omental sac and performing the pancreatic gland abdomination along a lower edge of its body and tail are followed by puncturing retroperitoneal fat with introducing components No.1 and No.2 therein. First, component No.1 consisting of dry lyophilized cryoprecipitate 50-70 g dissolved in normal saline 100 ml is slowly administered. Then 10 minutes later, the retroperitoneal fat is additionally punctured, and component No.2 consisting of NIH sterile thrombin dissolved in 5% s-aminocapronic acid 10 ml is introduced. An artificial fibrin barrier is formed in the retroperitoneal fat 5-7 minutes later by mixing and polymerising the two solutions.

EFFECT: method provides the effective treatment of pancreatonecrosis by forming the artificial fibrin barrier on the way of a potential impregnation of the retroperitoneal fat in an enzymatic fluid.

3 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: haemodilution is performed with using crystalloid solutions, nitroglycerin and antihypertensive drugs. The antihypertensive drug is presented by using 5% pentamine intermittently administered after the beginning of the anaesthetic induction; if the effect of pentamine occurred to be inadequate, nitroglycerin is infused in an amount of 10 ml as a 0.1% solution diluted in crystalloid solution 200 ml for maintaining reference arterial blood pressure of 80/50 mm Hg. The nitroglycerin solution is kept to be administered until the wound is sutured, while the additional antihypertensive and blood loss reducing effect is ensured by spinal anaesthesia; as a haemostatic agent, an officinal solution of tranexamic acid 5-10 ml is intraoperatively intravenously introduced under an endoprosthesis bed.

EFFECT: lower risk of postoperative complications and ensured controlled stable arterial blood pressure in the patient.

2 ex

FIELD: medicine.

SUBSTANCE: first, Fraxiparine is inhaled for 5-10 minutes. A dialysis solution for peritoneal dialysis containing extranyl is administered into the abdominal cavity 1-1.5 hours later through a catheter. The solution additionally contains: albumin in the concentration of 35-40 g/l, heparin in the concentration of 500-750 Unit/l and papaverine in the concentration of 50-100 mg/l. Every 6-8 hours after the beginning of exposure of the dialysis solution in the abdominal cavity, the Fraxiparine inhalations are repeated. The time of a single exposure of the dialysis solution in the abdominal cavity makes 12-18 hours.

EFFECT: method provides effective body detoxification in the given category of patients by providing a high toxin clearance owing to a continuous high osmotic concentration of the solution and the dilatation of pre-capillary peritoneal arterioles, prevented inspissation of the albumin solution to the colloidal state and its inactivation that reduces a rate of the dialysis solution exchanges.

3 ex

FIELD: veterinary medicine.

SUBSTANCE: method of growing quails consists in that the sodium hypochlorite solution obtained in electrochemical method, diluted with distilled water to a concentration of 100-200 mg/l, is used for free watering quails from the first days to 42 days old birds once in 7 days during a day.

EFFECT: invention enables to improve the performance of quail meat productivity, livestock safety, while simultaneous reducing the cost of feed for poultry live weight gain.

6 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention represents an irrigation solution containing sodium chloride, mono- and dibasic sodium phosphate, glycosaminoglycans, glucose or its derivatives, water-soluble cellulose or its derivatives, neuraminic acid, an antihypertensive agent and water.

EFFECT: irrigation solution is balanced; it possesses the anti-inflammatory, anti-oedemic and antihypertensive properties.

3 ex

FIELD: medicine.

SUBSTANCE: at the first stage a puncture of the right femoral artery or the right radial artery by Seldinger is performed with further successive catheterisation of the mouth of superior and inferior mesenteric arteries. After that, infusion of 0.5 ml of a 15% solution of xantinol nicotinate and 1.0 ml of a 2% lidocaine solution, diluted in 20.0 ml of a 0.9% solution of sodium chloride is performed. Introduction is carried out under X-ray control.

EFFECT: prevention of endotoxinemia development in the said category of patients due to reduction of spasm of the microcirculatory bed of the small intestine wall, and reduction of oedema and ischemia of the intestine mucosa, blocking the passage of nerve impulses to the intestine wall, which results in reduction of the intestine atony and reduction of translocation of endotoxins from the intestine lumen into the bloodstream.

1 ex

FIELD: medicine.

SUBSTANCE: ronkoleukin is administered in a dose of 500,000 units in a 0.9% physiological saline 20.0 ml. The prepared solution in an amount of 10.0 ml is administered into a round ligament of the liver through a catheter inserted under visual control. The rest amount of 10.0 ml is introduced into incisional wound edges on the 1st and 3rd postoperative days.

EFFECT: method provides stimulating local immunity in both the incisional wound, and the hepatoduodenal region ensured by a separate effect of cytokines on various groups of lymphatic nodes.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and aims at intraoperative and early postoperative infusion therapy. A method involves administering a crystalloid balanced solution of sterofundin iso and a balanced colloidal solution of tetraspan. In the intraoperative period, sterofundin is administered with tetraspan in the volume ratio 3:1. In the early postoperative period, for the first day, sterofundin and tetraspan are administered in the volume ratio 6:1.

EFFECT: method is simple, safe, enables effectively correcting aqueous electrolyte disorders, stabilising systemic hemodynamic parameters, causing no negative effect on haemostasis and electrolyte composition of the blood serum.

1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: group of inventions refers to veterinary science and aims at normalising metabolic processes, stimulating immune system and blocking mechanisms of infectious process with a risk of endogenous infection activation. A method for producing a combination immunometabolic preparation with anti-infectious activity involves dissolving succinic acid and levamisole in demineralised water with formalin added. According to the other aspect of the invention, the immunometabolic preparation additionally contains polyethylene glycol. The ingredients are used in the declared ratio.

EFFECT: using this group of inventions provides producing an injection form of the immunometabolic preparation with anti-infectious activity.

2 cl, 3 tbl

Up!